^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:bortezomib (Proteasome inhibitor) +
    Farydak (panobinostat) (HDAC inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    08/28/2015
    Excerpt:
    Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/23/2015
    Excerpt:
    FARYDAK, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.
    Secondary therapy:
    dexamethasone